Clinical trial
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid…
NCT00048321 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00048321 |
|---|---|
| Title | ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis |
| Official title | ISIS 104838-CS7, A Double-Blind, Placebo-Controlled, Randomized Trial of the Safety, Efficacy and Pharmacokinetic Profile of ISIS 104838 (TNF-alpha Antisense Oligonucleotide) Subcutaneous Injections in Active Rheumatoid Arthritis Patients |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | ISIS 104838 |
| Enrollment | 160 |
| Start date | Jan 1, 2002 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Oct 31, 2002 |
| Last update posted | Dec 5, 2022 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: